Bernard Escudier, MD
Cabozantinib (Cabometyx) was associated with an 8-month improvement in overall survival (OS) and a 4.7-month improvement in progression-free survival (PFS) compared with everolimus (Afinitor) in pretreated patients with advanced renal cell carcinoma (RCC) with bone metastases at baseline.1
The incidence of grade 3/4 adverse events (AEs) in patients with bone metastases was 73% in the cabozantinib arm compared with 51% for patients receiving everolimus. Among patients treated with cabozantinib, grade 3/4 AEs included fatigue (16% vs 6% with everolimus), diarrhea (14% vs 0), palmar-plantar erythrodysesthesia syndrome (8% vs 0%), asthenia (6% vs 2%), hypertension (6% vs 2%), and nausea (6% vs 0%).
- Escudier B, Powles T, Motzer RJ, et al. Cabozantinib, a new standard of care for patients with advanced renal cell carcinoma and bone metastases? Subgroup analysis of the METEOR trial [published online January 8, 2018]. J Clin Oncol doi: 10.1200/JCO.2017.74.7352.
- Choueiri TK, Escudier B, Powles T, et al. Cabozantinib versus everolimus in advanced renal-cell carcinoma. N Engl J Med. 2015;373(19):1814-1823.
... to read the full story